These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

8645 related articles for article (PubMed ID: 2280735)

  • 1. Optimization of 125I ophthalmic plaque brachytherapy.
    Astrahan MA; Luxton G; Jozsef G; Liggett PE; Petrovich Z
    Med Phys; 1990; 17(6):1053-7. PubMed ID: 2280735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Brachytherapy of ocular melanoma: physical and dosimetric aspects of 125I plaques].
    Bard JJ
    Bull Cancer Radiother; 1995; 82(3):295-305. PubMed ID: 8554879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive dosimetric comparison between (131)Cs and (125)I brachytherapy sources for COMS eye plaque implant.
    Zhang H; Martin D; Chiu-Tsao ST; Meigooni A; Thomadsen BR
    Brachytherapy; 2010; 9(4):362-72. PubMed ID: 20116342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The design and the dosimetry of bi-nuclide radioactive ophthalmic applicators.
    Flühs D; Anastassiou G; Wening J; Sauerwein W; Bornfeld N
    Med Phys; 2004 Jun; 31(6):1481-8. PubMed ID: 15259651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS.
    Chiu-Tsao ST; Astrahan MA; Finger PT; Followill DS; Meigooni AS; Melhus CS; Mourtada F; Napolitano ME; Nath R; Rivard MJ; Rogers DW; Thomson RM
    Med Phys; 2012 Oct; 39(10):6161-84. PubMed ID: 23039655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques.
    Puusaari I; Heikkonen J; Kivelä T
    Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3425-34. PubMed ID: 15452045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An interactive treatment planning system for ophthalmic plaque radiotherapy.
    Astrahan MA; Luxton G; Jozsef G; Kampp TD; Liggett PE; Sapozink MD; Petrovich Z
    Int J Radiat Oncol Biol Phys; 1990 Mar; 18(3):679-87. PubMed ID: 2318702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A practical approach to estimating optic disc dose and macula dose without treatment planning in ocular brachytherapy using
    Lee YC; Lin SC; Kim Y
    Radiat Oncol; 2018 Nov; 13(1):221. PubMed ID: 30424782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivered dose uncertainty analysis at the tumor apex for ocular brachytherapy.
    Morrison H; Menon G; Larocque MP; Jans HS; Weis E; Sloboda RS
    Med Phys; 2016 Aug; 43(8):4891. PubMed ID: 27487906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monte Carlo dosimetry for 103Pd, 125I, and 131Cs ocular brachytherapy with various plaque models using an eye phantom.
    Lesperance M; Martinov M; Thomson RM
    Med Phys; 2014 Mar; 41(3):031706. PubMed ID: 24593710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiobiology for eye plaque brachytherapy and evaluation of implant duration and radionuclide choice using an objective function.
    Gagne NL; Leonard KL; Rivard MJ
    Med Phys; 2012 Jun; 39(6):3332-42. PubMed ID: 22755715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy.
    Thomson RM; Taylor RE; Rogers DW
    Med Phys; 2008 Dec; 35(12):5530-43. PubMed ID: 19175111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformal episcleral plaque therapy.
    Astrahan MA; Luxton G; Pu Q; Petrovich Z
    Int J Radiat Oncol Biol Phys; 1997 Sep; 39(2):505-19. PubMed ID: 9308957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computer assisted treatment planning for 125I ophthalmic plaque radiotherapy.
    Ling CC; Chen GT; Boothby JW; Weaver K; Stuart A; Barnett C; Char D; Phillips TL
    Int J Radiat Oncol Biol Phys; 1989 Aug; 17(2):405-10. PubMed ID: 2753765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation complications and tumor control after 125I plaque brachytherapy for ocular melanoma.
    Jensen AW; Petersen IA; Kline RW; Stafford SL; Schomberg PJ; Robertson DM
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):101-8. PubMed ID: 16111577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of choroidal melanomas treated with eye physics: a 20-year review.
    Berry JL; Dandapani SV; Stevanovic M; Lee TC; Astrahan M; Murphree AL; Kim JW
    JAMA Ophthalmol; 2013 Nov; 131(11):1435-42. PubMed ID: 24008431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 125I eye plaque dose distribution including penumbra characteristics.
    de la Zerda A; Chiu-Tsao ST; Lin J; Boulay LL; Kanna I; Kim JH; Tsao HS
    Med Phys; 1996 Mar; 23(3):407-18. PubMed ID: 8815384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetric study of the 15 mm ROPES eye plaque.
    Granero D; Pérez-Calatayud J; Ballester F; Casal E; de Frutos JM
    Med Phys; 2004 Dec; 31(12):3330-6. PubMed ID: 15651616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the shielding effectiveness of silicone oil vitreous substitutes when used with Palladium-103 and Iodine-125 eye plaques.
    Yang YM; Chow PE; McCannel TA; Lamb JM
    Med Phys; 2019 Feb; 46(2):1006-1011. PubMed ID: 30554429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delivered dose changes in COMS plaque-based ocular brachytherapy arising from vitrectomy with silicone oil replacement.
    Morrison H; Larocque MP; Menon G; Sloboda RS; Weis E
    Brachytherapy; 2019; 18(5):668-674. PubMed ID: 31272841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 433.